CAS: 1372540-25-4 - GSK2636771
Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
---|---|---|---|---|
GSK2636771 REF: IN-DA009CC3CAS: 1372540-25-4 | 98% | A consultar | Mar 07 Ene 25 | |
GSK2636771 REF: TM-T2073CAS: 1372540-25-4 | 98.58% - ≥95% | 42,00 €~535,00 € | Mar 14 Ene 25 | |
GSK2636771 REF: TR-G797495CAS: 1372540-25-4 | - - - | 195,00 € | Mié 15 Ene 25 | |
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid REF: 3D-FM102909CAS: 1372540-25-4 | Min. 95% | - - - | Producto descatalogado |
Ref: IN-DA009CC3
1mg | 47,00 € | ||
5mg | 99,00 € | ||
10mg | 111,00 € | ||
50mg | 247,00 € | ||
100mg | 545,00 € | ||
250mg | A consultar |
Entrega estimada en Estados Unidos, el Martes 7 de Enero de 2025
GSK2636771
CAS:1372540-25-4
GSK2636771, an effective, specific, orally bioavailable, PI3Kβ inhibitor, has been used in cancer, lymphoma, solid …
Fórmula:
C22H22F3N3O3
Pureza:
98.58% - ≥95%
Forma y color:
Solid
Peso molecular:
433.42
Ref: TM-T2073
1mg | 42,00 € | ||
2mg | 56,00 € | ||
5mg | 87,00 € | ||
10mg | 147,00 € | ||
25mg | 248,00 € | ||
50mg | 353,00 € | ||
100mg | 535,00 € | ||
1mL*10mM (DMSO) | 89,00 € |
Entrega estimada en Estados Unidos, el Martes 14 de Enero de 2025
GSK2636771
Producto controladoCAS:1372540-25-4
Fórmula:
C22H22F3N3O3
Forma y color:
Neat
Peso molecular:
433.42
Ref: TR-G797495
2500µg | 195,00 € |
Entrega estimada en Estados Unidos, el Miércoles 15 de Enero de 2025
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid
CAS:1372540-25-4
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid (BIC) is a strain that is categorized as a cancer drug. It has …
Fórmula:
C22H22F3N3O3
Pureza:
Min. 95%
Peso molecular:
433.42 g/mol
Ref: 3D-FM102909
5mg | Descatalogado | Solicitar información | |
10mg | Descatalogado | Solicitar información | |
25mg | Descatalogado | Solicitar información |